Revolution Medicines, Inc. (RVMD) Return on equity 2020–2025
Revolution Medicines, Inc. (RVMD) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-69.3%FY2025 · since FY2020: -22.8% → -69.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -69.3% | -42.9 pp |
| FY2024 | -26.5% | -2.6 pp |
| FY2023 | -23.9% | +12.4 pp |
| FY2022 | -36.3% | -5.2 pp |
| FY2021 | -31.0% | -8.3 pp |
| FY2020 | -22.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RVMD financial trends
RVMD RevenueRVMD Net incomeRVMD Net marginRVMD Gross profitRVMD Gross marginRVMD Operating incomeRVMD Operating marginRVMD Operating cash flowRVMD Free cash flowRVMD Capital expendituresRVMD Stock buybacksRVMD Dividends paidRVMD Total assetsRVMD Total liabilitiesRVMD Shareholders’ equityRVMD overview →